Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D05ZSX
|
|||
| Former ID |
DIB004863
|
|||
| Drug Name |
NN-8828
|
|||
| Synonyms |
NNC-114-0005; NNC-0114-0000-0005; Anti-IL-21 (inflammation), Novo Nordisk; MIL-21 monoclonal antibody (autoimmune/chronic inflammatory disease), ZymoGenetics; Anti-IL-21 mAb (autoimmune/chronic inflammatory disease), Novo Nordisk; Anti-IL-21 mAb (autoimmune/chronic inflammatory disease), ZymoGenetics; Anti-IL-21 monoclonal antibody (autoimmune/chronic inflammatory disease), ZymoGenetics
Click to Show/Hide
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Autoimmune diabetes [ICD-11: 5A10] | Phase 1 | [1] | |
| Company |
ZymoGenetics Inc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin-21 (IL21) | Target Info | . | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Jak-STAT signaling pathway | ||||
| Inflammatory bowel disease (IBD) | ||||
| Panther Pathway | Interleukin signaling pathway | |||
| WikiPathways | Allograft Rejection | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01208506) First-in-Man Trial of NNC114-0005 in Healthy Subjects and Subjects With Rheumatoid Arthritis. U.S. National Institutes of Health. | |||
| REF 2 | Handbook of Therapeutic Antibodies. 2014. 1. Page(995). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.